5 Star
.
.
.
.
.

NASHVILLE -- Among multiple sclerosis (MS) patients experiencing breakthrough disease on standard-dose once-a-week interferon beta 1-a (IFN-1α), switching to twice-weekly dosing may offer advantages, a researcher reported here.

More than half of patients with breakthrough disease and adequate follow-up (26/52 patients) who were switched to twice-weekly treatment had no further clinical relapses, new T2 lesions, or enhanced lesions on MRI, or worsening of Expanded Disability Status Scale (EDSS) during at least 14 months (range 14 to 192 months) of follow-up, according to Robert Baumhefner, MD, of the VA Greater Los Angeles Healthcare System.

.

Harvey Weinstein hit with rape allegation in new lawsuit

Weinstein told her the meeting would continue at the Tribeca Grand Hotel after he finished editing a movie, the complaint says. The Associated Press does not identify alleged victims of sexual assaults unless they come forward publicly.
  • .
    .